SUBLICENSE AGREEMENTSublicense Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
THIS SUBLICENSE Agreement (“Agreement”) is entered into on September 26, 2017 (the “Effective Date”) by and between BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”), dated as of March 21, 2018, is entered into between Ascendance Biotechnology, Inc., a Delaware corporation (the “Company”), and AgeX Therapeutics, Inc., a Delaware corporation (“Buyer”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
This Registration Rights Agreement (“Agreement”) is entered into as of , 2017 by and between AgeX Therapeutics, Inc., a California corporation (the “Company”) and the undersigned.
SHARED FACILITIES AND SERVICES AGREEMENTShared Facilities and Services Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations
This Agreement is made as of August 17, 2017 (the Effective Date) by and between BioTime, Inc. (BioTime) and AgeX Therapeutics, Inc. (AgeX).
FIRST AMENDMENT TO SUBLICENSE AGREEMENTSublicense Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO SUBLICENSE AGREEMENT (“First Amendment”) is entered into on November 8, 2017 (the “Effective Date”) by and between ORTHOCYTE CORPORATION, a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“OrthoCyte”), BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“BioTime”, and together with OrthoCyte, “BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).
SUBLICENSE AGREEMENTSublicense Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
THIS SUBLICENSE Agreement (“Agreement”) is entered into this 17th day of August, 2017 (the “Effective Date”) by and between ORTHOCYTE CORPORATION, a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“OrthoCyte”), BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“BioTime”, and together with OrthoCyte, “BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).
LICENSE AGREEMENTLicense Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
This License Agreement (“Agreement”) is made and entered into as of August 17, 2017 (the “Effective Date”), by and between ES Cell International Pte Ltd., a corporation wholly owned by BioTime, Inc. (“BioTime”) and duly established under the laws of Singapore, having its registered office at 1010 Atlantic Avenue, Alameda, CA 94501 (“ESI”), and AgeX Therapeutics, Inc., a Delaware corporation (“AgeX”). ESI and AgeX are sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties”.
TAX MATTERS AGREEMENT BY AND AMONG BIOTIME, INC. AND ITS AFFILIATED COMPANIES AND AGEX THERAPEUTICS, INC. AND ITS AFFILIATED COMPANIES August 17, 2017 TAX MATTERS AGREEMENT BY AND BETWEEN BIOTIME, INC. AND AGEX THERAPEUTICS, INC.Tax Matters Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Tax Matters Agreement (the “Agreement”) is entered into as of August 17, 2017, by and between BioTime, Inc., a California corporation (“BioTime”), and AgeX Therapeutics, Inc., a Delaware corporation (“AgeX”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LICENSE AGREEMENT (“First Amendment”) is entered into on November 8, 2017 (the “Effective Date”) by and between BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).
EMPLOYEE MATTERS AGREEMENT by and between BIOTIME, INC. and AGEX THERAPEUTICS, INC. Dated as of August 17, 2017Employee Matters Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This EMPLOYEE MATTERS AGREEMENT (this “Agreement”), dated as of August 17, 2017, is entered into by and between BioTime, Inc. (“BioTime”), a California corporation, and AgeX Therapeutics, Inc. (“AgeX”), a Delaware corporation and a wholly owned subsidiary of BioTime. “Party” or “Parties” means BioTime or AgeX, individually or collectively, as the case may be.
LICENSE AGREEMENTLicense Agreement • July 19th, 2018 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • California
THIS LICENSE Agreement (“Agreement”) is entered into this 17th day of August, 2017 (the “Effective Date”) by and between BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).
